<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James N George, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adam Cuker, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombotic microangiopathy (TMA) describes a specific pathologic lesion in which abnormalities in the vessel wall of arterioles and capillaries lead to microvascular thrombosis. TMA is a pathologic diagnosis made by tissue biopsy. However, it is commonly inferred from the observation of microangiopathic hemolytic anemia (MAHA) and thrombocytopenia in the appropriate clinical setting. Immune thrombotic thrombocytopenic purpura (TTP) was the first of the primary TMAs to be described and is perhaps the best understood of the TMAs pathophysiologically. TTP is unique among the primary TMAs for minimal abnormalities of kidney function, despite microthrombi observed throughout the kidney.
        </p>
        <p>
         The pathophysiology of immune TTP, complement-mediated TMA, Shiga toxin-induced TMA (hemolytic uremic syndrome [ST-HUS]), and some of the rare inherited TMAs will be reviewed here.
        </p>
        <p>
         The pathophysiologies of hereditary TTP and drug-induced TMA (also called drug-induced TTP) are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/101504.html" rel="external">
          "Hereditary thrombotic thrombocytopenic purpura (hTTP)", section on 'Genetics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         Separate topic reviews also discuss the general approach to the patient with a suspected TMA (see
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         ), and diagnosis and management of specific conditions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immune TTP – (See
         <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">
          "Diagnosis of immune TTP"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">
          "Immune TTP: Initial treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary TTP – (See
         <a class="medical medical_review" href="/z/d/html/101504.html" rel="external">
          "Hereditary thrombotic thrombocytopenic purpura (hTTP)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug-induced TMA – (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7197.html" rel="external">
          "Kidney disease following hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy-associated syndromes – (See
         <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">
          "Thrombocytopenia in pregnancy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HUS – (See
         <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">
          "Overview of hemolytic uremic syndrome in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">
          "Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          HISTOPATHOLOGY OF TMA
         </span>
        </p>
        <p class="headingAnchor" id="H9813390">
         <span class="h2">
          Endothelial changes and microthrombi
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histopathology of TTP and other primary TMAs is distinguished from that of systemic conditions such as systemic infections and malignancies, which may also cause microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and/or disseminated intravascular coagulation (DIC). In the primary TMAs, a heritable (genetic) or acquired abnormality promotes formation of platelet microthrombi in the microvasculature.
        </p>
        <p>
         TMA is characterized by small vessel changes including swelling of endothelial cells and the subendothelial space, along with vessel wall thickening and platelet microthrombi, typically in small arterioles and capillaries [
         <a href="#rid1">
          1
         </a>
         ]. These changes can obliterate the vessel lumen, especially in smaller vessels, and lead to hyaline occlusion. In some cases, endothelial cell proliferation and/or vessel wall dilatation (eg, microaneurysms) have been seen in the affected arterioles. Large-vessel thrombosis is not typical of TTP or other primary TMAs.
        </p>
        <p>
         Similar histologic findings of TMA may also be seen in other disorders such as malignant hypertension, systemic lupus erythematosus, scleroderma, antiphospholipid syndrome, and kidney transplant rejection.
        </p>
        <p>
         Examples of the typical sites of organ involvement include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney
         </strong>
         – Kidney involvement by TMA is typical of all primary TMA syndromes. Severe acute kidney injury is a prominent feature of all primary TMA syndromes except TTP, in which it is rare. Pathologic changes in the kidney include thrombi in the arterioles  (
         <a class="graphic graphic_picture graphicRef54840" href="/z/d/graphic/54840.html" rel="external">
          picture 1
         </a>
         ) and glomeruli  (
         <a class="graphic graphic_picture graphicRef63511" href="/z/d/graphic/63511.html" rel="external">
          picture 2
         </a>
         ). Urinary findings are nonspecific and may include hematuria, hemoglobinuria, and/or proteinuria. (See
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">
          "Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These pathologic changes are similar for all of the TMAs; however, they may be helpful in distinguishing between a TMA and other causes of renal failure with a nondiagnostic urine sediment [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7188.html" rel="external">
          "Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central nervous system
         </strong>
         – Central nervous system involvement may occur in any of the primary TMA syndromes. Clinical features of neurologic involvement may be most common in patients with TTP. Neurologic manifestations, when they occur, may be mild, with headache and transient confusion, or severe, with tonic-clonic seizures, stroke, and/or coma. Focal abnormalities often occur in TTP, including episodes of numbness or weakness localized to an arm or hand or side of the face, or transient aphasia or vision impairment.
        </p>
        <p>
        </p>
        <p>
         Similar TMA lesions of the microvasculature in the heart, skin, and/or gastrointestinal tract are inferred from clinical findings such as acute coronary syndrome, purpuric skin lesions, and gastrointestinal symptoms (eg, abdominal pain, bloody diarrhea). An exception is pulmonary involvement, which is rarely clinically evident despite microvascular thrombi in the lungs [
         <a href="#rid3">
          3
         </a>
         ]. Autopsy of patients who have died with an acute episode of TTP demonstrates microvascular thrombi characteristic of TTP in almost all organs [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2626376">
         <span class="h2">
          Hematologic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematologic findings are the same in TTP and other primary TMA syndromes. The characteristic and constant feature is microangiopathic hemolytic anemia (MAHA). MAHA was first described in 25 patients 60 years ago [
         <a href="#rid5">
          5
         </a>
         ]. The etiologies of MAHA in these patients predicted the etiologies that we recognize today: TTP, malignant hypertension, kidney diseases, systemic lupus erythematosus, and metastatic cancer. Some degree of thrombocytopenia also occurs in almost all primary TMAs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MAHA
         </strong>
         – MAHA is caused by mechanical RBC fragmentation that occurs as RBCs traverse platelet-rich thrombi in the microcirculation. The result of RBC fragmentation is schistocytes, which typically are prominent on the peripheral blood smear  (
         <a class="graphic graphic_picture graphicRef70851" href="/z/d/graphic/70851.html" rel="external">
          picture 3
         </a>
         ). The electron micrograph illustrates how schistocytes are formed  (
         <a class="graphic graphic_picture graphicRef81610" href="/z/d/graphic/81610.html" rel="external">
          picture 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombocytopenia
         </strong>
         – Thrombocytopenia is due to platelet consumption in microthrombi throughout the microcirculation. Thrombocytopenia may be only mild or moderate in many of the primary TMA syndromes, but in patients with TTP it is typically severe (platelet count almost always &lt;30,000/microL).
        </p>
        <p>
        </p>
        <p>
         Bone marrow evaluation (aspiration/biopsy) typically is not performed in TTP or other primary TMAs. If it is performed, it shows normal trilineage maturation with increased thrombopoiesis and erythropoiesis to compensate for consumption of platelets and RBCs in the peripheral circulation. A bone marrow evaluation is appropriate when the clinical features of a primary TMA are not clear and an alternative diagnosis such as a systemic malignancy is suspected [
         <a href="#rid6">
          6
         </a>
         ]. A systemic malignancy should be considered in all patients who have a history of cancer, as occult systemic cancer can mimic TTP [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The white blood cell (WBC) count is normal in primary TMAs; leukocytosis or leukopenia suggests that another disorder such as myelodysplasia, systemic malignancy, or megaloblastic anemia is responsible for abnormalities of RBC morphology and thrombocytopenia.
        </p>
        <p>
         Abnormalities of coagulation are uncommon in TTP and other primary TMAs. This is a major clinical feature that distinguishes primary TMAs from other causes of MAHA and thrombocytopenia such as systemic infection or malignancy, which are often associated with disseminated intravascular coagulation (DIC). DIC is characterized by prolongation of the prothrombin time (PT) and activated partial thromboplastin time (aPTT), increased D-dimer, and reduced fibrinogen. In occasional patients with TTP, organ ischemia may be severe enough to cause DIC, but this is rare. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          TTP PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H199371">
         <span class="h2">
          Deficient ADAMTS13 activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         TTP is caused by severely deficient activity of the ADAMTS13 (
         <strong>
          A
         </strong>
         <strong>
          D
         </strong>
         isintegrin
         <strong>
          A
         </strong>
         nd
         <strong>
          M
         </strong>
         etalloprotease with a
         <strong>
          T
         </strong>
         hrombo
         <strong>
          S
         </strong>
         pondin type 1 motif, member
         <strong>
          13
         </strong>
         ) protease, clinically defined as an activity level &lt;10 percent [
         <a href="#rid1">
          1
         </a>
         ]. ADAMTS13 is a plasma protease that was initially defined by its function as a von Willebrand factor (VWF)-cleaving protease. It cleaves the ultralarge, string-like molecules of VWF that are synthesized by endothelial cells and secreted into the plasma but remain attached to the endothelial surface. This normal cleavage to smaller sized multimers prevents ultralarge multimers from accumulating, especially in areas of high shear stress (eg, small arterioles and capillaries). Shear stress leads to a conformational change in the large VWF multimers that exposes the ADAMTS13 cleavage site. When protease activity is reduced, ultralarge VWF multimers accumulate on the endothelial surface, where platelets attach and accumulate [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Platelet adhesion'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">
          "Pathophysiology of von Willebrand disease", section on 'VWF functions'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metalloprotease refers to the metal-dependent enzymatic domain of the protein, which cleaves VWF. Its catalytic activity is facilitated by the metal zinc (as well as calcium ions).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disintegrin refers to the domain of the protein that interferes with cell-cell interactions, which might include interactions between platelets and endothelial cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombospondin refers to the domain of the protein similar to thrombospondins, which have antiangiogenic properties.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ADAMTS13 is the 13
         <sup>
          th
         </sup>
         member of the ADAMTS family to be described.
        </p>
        <p>
        </p>
        <p>
         ADAMTS13 is primarily synthesized in hepatic stellate cells [
         <a href="#rid9">
          9
         </a>
         ]. It may also be synthesized by endothelial cells and megakaryocytes [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         A severe reduction in ADAMTS13 activity (typically to less than 10 percent of normal, although ADAMTS13 activity ≥10 percent is not rare [
         <a href="#rid10">
          10
         </a>
         ]) is present in almost all patients with acute TTP, although diagnosis is always made using a combination of clinical and laboratory findings. In contrast, modest reductions may occur in a variety of medical conditions such as sepsis or liver disease and are not thought to cause clinical disease. Use of ADAMTS13 activity testing in the diagnosis of TTP is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">
          "Diagnosis of immune TTP", section on 'Reduced ADAMTS13 activity'
         </a>
         .)
        </p>
        <p>
         However, a severe deficiency of ADAMTS13 activity alone is not sufficient to cause TTP.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with hereditary ADAMTS13 deficiency may have no signs or symptoms of TTP until they have a triggering exposure such as an infection or pregnancy [
         <a href="#rid11">
          11-14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/101504.html" rel="external">
          "Hereditary thrombotic thrombocytopenic purpura (hTTP)", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some individuals with severe ADAMTS13 deficiency due to an autoantibody continue to have severe deficiency in clinical remission without clinical findings [
         <a href="#rid15">
          15,16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">
          "Immune TTP: Management following recovery from an acute episode and during remission", section on 'Natural history of ADAMTS13 activity during remission'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These observations suggest that additional factors such as an acute inflammatory or prothrombotic stimulus may be responsible for triggering clinical manifestations.
        </p>
        <p class="headingAnchor" id="H2629789">
         <span class="h2">
          Causes of ADAMTS13 deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major cause of severe ADAMTS13 deficiency is an autoantibody; inherited gene mutations account for a small additional number of cases. Additional conditions may reduce ADAMTS13 activity, including sepsis, cardiac surgery, pancreatitis, and liver disease [
         <a href="#rid17">
          17-21
         </a>
         ]. However, these conditions are extremely unlikely to lower ADAMTS13 activity to a level likely to cause TTP. (See
         <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">
          "Diagnosis of immune TTP", section on 'Reduced ADAMTS13 activity'
         </a>
         .)
        </p>
        <p>
         ADAMTS13 activity also appears to decrease during the last two trimesters of pregnancy, declining to the lowest levels at 36 to 40 weeks of gestation and the early puerperium [
         <a href="#rid20">
          20,22
         </a>
         ]. Higher levels of VWF also appear to reduce ADAMTS13 activity, as illustrated by kinetic studies in healthy individuals treated with
         <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">
          desmopressin
         </a>
         , which causes release of VWF from endothelial cells, with a concomitant reduction of ADAMTS13 activity, likely due to consumption [
         <a href="#rid23">
          23
         </a>
         ]. These further reductions in ADAMTS13 activity and/or inflammatory stimuli in a patient with an underlying anti-ADAMTS13 autoantibody or hereditary ADAMTS13 deficiency may act as triggers for an acute episode of TTP.
        </p>
        <p>
         High levels of free hemoglobin in the circulation (eg, in severe hemolytic anemia) or hemolysis in the blood sample after collection may interfere with laboratory measurement of ADAMTS13 activity, giving a false impression of severe deficiency [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">
          "Diagnosis of immune TTP", section on 'ADAMTS13 testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2627163">
         <span class="h3">
          Inhibitory antibodies to ADAMTS13
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast majority of cases of TTP (approximately 95 percent) are immune, due to inhibitory autoantibodies against ADAMTS13 [
         <a href="#rid1">
          1,25
         </a>
         ]. Risk factors for development of the autoantibodies are not clearly defined, although immune TTP is more common in young females, and the relative incidence is increased in Black individuals [
         <a href="#rid26">
          26
         </a>
         ]. The incidence of immune TTP also may be increased in individuals with other autoimmune conditions such as systemic lupus erythematosus (SLE) or certain human leukocyte antigen (HLA) types, but most affected patients do not have an underlying rheumatologic or immunologic condition [
         <a href="#rid27">
          27,28
         </a>
         ]. Additional autoimmune disorders occur in 20 percent of patients with immune TTP [
         <a href="#rid10">
          10
         </a>
         ] (See
         <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">
          "Diagnosis of immune TTP", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         The titer of the ADAMTS13 autoantibody may have implications for therapy and prognosis. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In plasma from patients with immune TTP, the concentration of
         <a class="drug drug_general" data-topicid="143378" href="/z/d/drug information/143378.html" rel="external">
          recombinant ADAMTS13
         </a>
         required to normalize ADAMTS13 activity correlated strongly with the inhibitor titer [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study correlated higher initial inhibitor titers with a greater incidence of refractory disease and a greater likelihood of inhibitor "boosting" (ie, increasing inhibitor titer) during initial therapy [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99124.html" rel="external">
          "Immune TTP: Treatment of clinical relapse", section on 'Refractory disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional studies have shown correlations between a higher inhibitor titer and a greater likelihood of disease relapse and/or reduced survival [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99124.html" rel="external">
          "Immune TTP: Treatment of clinical relapse", section on 'Clinical relapse'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Analysis of patient autoantibodies to ADAMTS13 has indicated that many of these antibodies react with a cysteine-rich spacer domain in the ADAMTS13 protein, although others react with other domains [
         <a href="#rid31">
          31-33
         </a>
         ]. Some autoantibodies inhibit enzyme activity, while others may increase clearance of the protein; these latter so-called "non-neutralizing" antibodies are not detected in all commercial ADAMTS13 activity assays and may account for the failure to document an inhibitor in some patients [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2627181">
         <span class="h3">
          ADAMTS13 gene variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary TTP caused by biallelic pathogenic variants in the
         <em>
          ADAMTS13
         </em>
         gene is much less common than immune TTP. Additional details about the types of pathogenic variants seen, their effects on ADAMTS13 function, and the International Hereditary TTP Registry (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fttpregistry.net%2F&amp;token=VEYs6REUOvbP0Un19sKXqun%2FQbl5dJk8xTIxl90ITCM%3D&amp;TOPIC_ID=1331" target="_blank">
          www.ttpregistry.net
         </a>
         ) are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/101504.html" rel="external">
          "Hereditary thrombotic thrombocytopenic purpura (hTTP)", section on 'Genetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H904569175">
         <span class="h2">
          Consequences of ADAMTS13 deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         ADAMTS13 is a protease that cleaves ultra-large, string-like multimers of VWF that are attached to the endothelial surface in areas of high shear stress. These VWF multimers bind to platelets and appear to promote microvascular thrombosis.
        </p>
        <p>
         The importance of the VWF-platelet interaction in TTP pathogenesis is illustrated by clinical observations in patients treated with
         <a class="drug drug_general" data-topicid="120300" href="/z/d/drug information/120300.html" rel="external">
          caplacizumab
         </a>
         , a monoclonal antibody that interferes with VWF-platelet interactions. Caplacizumab treatment can result in prompt, significant clinical improvement despite persistent ADAMTS13 deficiency [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">
          "Immune TTP: Initial treatment", section on 'Anti-VWF (caplacizumab)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H200332">
         <span class="h1">
          COMPLEMENT-MEDIATED TMA PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Defective complement regulation is responsible for complement-mediated TMA (CM-TMA), which can affect children or adults [
         <a href="#rid1">
          1
         </a>
         ]. We avoid using the term "atypical hemolytic uremic syndrome (aHUS)" to describe CM-TMA because it was originally intended as a nonspecific diagnostic term for children with non-diarrheal HUS. The term "aHUS" does not specify a mechanism or an appropriate therapy.
        </p>
        <p class="headingAnchor" id="H109385">
         <span class="h2">
          Consequences of excessive complement activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complement is a major component of the innate immune system. The complement cascade can cause lysis of target cells by forming a pore in the cell membrane. Any cell can be a target, including micro-organisms and host cells. The alternative pathway (see
         <a class="medical medical_review" href="/z/d/html/3968.html" rel="external">
          "Complement pathways", section on 'Alternative pathway'
         </a>
         ) is responsible for protecting self-cells from inappropriate complement-mediated attack, and failure of normal control mechanisms to downregulate the alternative pathway may lead to endothelial damage. Specific complement regulatory proteins responsible for protecting self-cells from inappropriate complement activity include soluble factors such as complement factor H (CFH) and membrane-bound factors such as membrane cofactor protein (MCP), decay accelerating factor (DAF), and thrombomodulin (TM) [
         <a href="#rid37">
          37,38
         </a>
         ]. These factors promote inactivation of membrane attack complex components. CFH and TM act as cofactors in the proteolytic inactivation of C3b by complement factor I (CFI). Loss of these protective factors may cause TMA by a variety of mechanisms.
        </p>
        <p>
         Examples of the crosstalk between complement and other processes include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Activation of complement triggers a variety of inflammatory responses. (See
         <a class="medical medical_review" href="/z/d/html/3920.html" rel="external">
          "Overview and clinical assessment of the complement system"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endothelial cells express receptors for complement; they are also susceptible to complement attack and injury. (See
         <a class="medical medical_review" href="/z/d/html/1330.html" rel="external">
          "The endothelium: A primer", section on 'Complement-mediated endothelial cell injury'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney cells appear to be especially sensitive to complement activation, which may explain the predominance of acute kidney injury in complement-mediated TMA. (See
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3920.html" rel="external">
          "Overview and clinical assessment of the complement system", section on 'Alternative pathway activation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         von Willebrand factor (VWF) may activate complement. (See
         <a class="local">
          'Interactions between VWF and the alternative complement pathway'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemostatic factors involved in the clotting cascade, especially those with regulatory roles, interact with complement proteins; the specific mechanisms and their importance are less well understood. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Synergy and crosstalk among these processes make it challenging to dissect their individual contributions to each TMA syndrome.
        </p>
        <p class="headingAnchor" id="H109398">
         <span class="h2">
          Inhibitory antibodies to complement factor H
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acquired complement-mediated TMA can be caused by autoantibodies to complement factor H; in some cases, there is a coexisting complement gene mutation. The relative contribution of these acquired inhibitors to clinical disease is unknown [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">
          "Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS", section on 'Autoantibodies against CFH'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children", section on 'Complement antibodies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H200352">
         <span class="h2">
          Complement gene variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         TMA can occur as a result of a pathogenic variant in one of several genes encoding complement factors. Factors H, I, B (also called CFH, CFI, and CFB), C3, and CD46 (also called membrane cofactor protein [MCP]) have been implicated. Heterozygosity for a pathogenic variant may be sufficient to cause clinical manifestations, in contrast to variants in the
         <em>
          ADAMTS13
         </em>
         gene in hereditary TTP, which require homozygosity or compound heterozygosity, with biallelic
         <em>
          ADAMTS13
         </em>
         variants. Specific complement factor gene variants and their role in causing a TMA are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children", section on 'Genetic variants'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">
          "Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS", section on 'Pathogenic sequence variants in complement genes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18418427">
         <span class="h2">
          Interactions between VWF and the alternative complement pathway
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although relatively less well studied, there may be interactions between the von Willebrand factor (VWF) and complement regulators. As an example, endothelial-anchored ultralarge strings of VWF have been shown to serve as an activating surface for the alternative pathway of complement [
         <a href="#rid40">
          40-42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3968.html" rel="external">
          "Complement pathways", section on 'Alternative pathway'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4972629">
         <span class="h1">
          SHIGA TOXIN-INDUCED TMA (ST-HUS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with an enteric organism that produces Shiga toxin is responsible for most cases of childhood hemolytic uremic syndrome (HUS). Childhood HUS caused by Shiga toxin is also called ST-HUS.
        </p>
        <p>
         Most cases of ST-HUS occur in children under five years old, but ST-HUS can also occur in adults. (See
         <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">
          "Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS"
         </a>
         .)
        </p>
        <p>
         In the United States and Europe, the organism responsible for ST-HUS typically is an
         <em>
          Escherichia coli
         </em>
         such as O157:H7, O111, or O104:H4 [
         <a href="#rid43">
          43-46
         </a>
         ].
         <em>
          Shigella
         </em>
         species may be more common as a source of Shiga toxin in Asia.
        </p>
        <p>
         Although large outbreaks are widely publicized, endemic/sporadic cases of ST-HUS are much more common [
         <a href="#rid47">
          47
         </a>
         ]. A variety of improperly prepared foods, especially beef, have been implicated as the source of infection. (See
         <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">
          "Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention", section on 'Transmission'
         </a>
         .)
        </p>
        <p>
         Examples of some of the major outbreaks include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Europe in 2011, correlated with ingestion of raw bean sprouts [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         United States in 2018, correlated with romaine lettuce [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other vegetables and meats, and exposure to livestock at farms, have also been implicated.
        </p>
        <p>
         The clinical presentation (eg, bloody diarrhea, acute kidney injury, hematologic findings of TMA) and appropriate management, which generally involves supportive care, are presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">
          "Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">
          "Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">
          "Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110454">
         <span class="h1">
          OTHER PRIMARY TMAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of other gene mutations have been associated with TMA. An understanding of the relative importance of these defects is evolving, facilitated by advances in recognition of these entities and availability of diagnostic testing [
         <a href="#rid1">
          1,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H110503">
         <span class="h2">
          Regulators of clotting or fibrinolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic variants in genes that encode regulators of the coagulation cascade have been implicated in inherited TMAs [
         <a href="#rid1">
          1
         </a>
         ]. The implicated factors are generally negative regulators of coagulation or fibrinolysis that also crosstalk with complement factors. The relative contributions of altered coagulation and altered complement activity in the pathogenesis of these TMAs have not been elucidated. Affected individuals generally present in infancy or early childhood.
        </p>
        <p>
         In contrast, pathogenic variants in genes that encode coagulation factors themselves have not been described in inherited TMA syndromes; rather, these types of variants appear to cause excessive bleeding (hemophilia) or excessive clotting (thrombophilia).
        </p>
        <p class="headingAnchor" id="H110461">
         <span class="h3">
          DGKE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biallelic pathogenic variants in the
         <em>
          DGKE
         </em>
         gene, encoding diacylglycerol kinase epsilon (DGKE), have been reported in several independent kindreds with a familial TMA [
         <a href="#rid50">
          50-52
         </a>
         ]. Homozygous or compound heterozygous pathogenic variants may be seen.
        </p>
        <p>
         DGKE is produced by endothelial cells, renal podocytes, and platelets. It is involved in protein kinase C (PKC) signaling, which increases endothelial cell production of several hemostatic factors including von Willebrand factor (VWF), plasminogen activator inhibitor 1 (PAI-1), platelet activating factor (PAF), and tissue factor (TF), as well as the antithrombotic factor tissue-type plasminogen activator (TPA) [
         <a href="#rid50">
          50
         </a>
         ]. DGKE also appears to be important for endothelial cell migration and angiogenesis [
         <a href="#rid53">
          53
         </a>
         ]. It is unclear what roles DGKE plays in complement activation, with some research suggesting only a small contribution to the expression of membrane cofactor protein (MCP, also called CD46) on endothelial cell surfaces, and other research showing more dramatic complement dysregulation [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H110522">
         <span class="h3">
          Thrombomodulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic variants in the
         <em>
          THBD
         </em>
         gene, encoding thrombomodulin (TM), have been described in cases of inherited TMA [
         <a href="#rid55">
          55,56
         </a>
         ]. Heterozygosity for a pathogenic variant in
         <em>
          THBD
         </em>
         may be sufficient to cause clinical manifestations, in contrast to hereditary TTP, which requires homozygosity or compound heterozygosity for pathogenic variants in
         <em>
          ADAMTS13
         </em>
         .
        </p>
        <p>
         TM is produced by endothelial cells. It regulates both the coagulation and the complement cascades. Its better established role in coagulation is as a membrane surface cofactor for thrombin in the activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI). These activities serve to dampen coagulation and fibrinolysis, respectively. Activated TAFI (TAFIa) functions as a basic carboxypeptidase and inactivates both C3a and C5a efficiently. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Activated protein C and protein S'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'CPB2/TAFI'
         </a>
         .)
        </p>
        <p>
         TM also plays a role in inactivating complement. It serves as a cofactor for factor I in C3b inactivation, and it promotes inactivation of C3a and C5a via TAFI [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H110535">
         <span class="h2">
          Regulators of vitamin B12 metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         TMA has been reported in individuals with pathogenic variants in the
         <em>
          MMACHC
         </em>
         gene, which encodes an enzyme involved in vitamin B12 (cobalamin) metabolism. Deficiency of this enzyme causes methylmalonic aciduria (MMA) and homocystinuria type C [
         <a href="#rid57">
          57-60
         </a>
         ]. Homozygosity or compound heterozygosity appears to be required for clinical disease. While this TMA has generally been reported in children, this may be because adults have not been evaluated [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         Infants with cobalamin C disease, a type of MMA, present with a variety of neurologic and developmental findings. Plasma homocysteine levels are markedly elevated, whereas plasma cobalamin levels are normal. (See
         <a class="medical medical_review" href="/z/d/html/2927.html" rel="external">
          "Organic acidemias: An overview and specific defects", section on 'Methylmalonic acidemia'
         </a>
         .)
        </p>
        <p>
         Complete responses of this TMA to therapy with high-dose cobalamin, folinic acid (
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         ), and
         <a class="drug drug_general" data-topicid="8598" href="/z/d/drug information/8598.html" rel="external">
          betaine
         </a>
         have been reported [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p>
         Evaluation for these abnormalities in cobalamin metabolism is available by routine laboratory testing (by measuring serum homocysteine and methylmalonic acid levels). These tests are appropriate for individuals with unexplained TMA. (See
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110549">
         <span class="h2">
          Drug-induced TMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug-induced TMA (DITMA) has been reported following exposure to several types of drugs, illicit substances, and over-the-counter remedies, especially those containing
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         (
         <a class="graphic graphic_table graphicRef60296" href="/z/d/graphic/60296.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid62">
          62
         </a>
         ]. The mechanism can be immune (autoantibody-mediated) mediated or non-immune.
        </p>
        <p>
         Our approach to the diagnosis and management of DITMA is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2050874474">
         <span class="h1">
          COVID-19-ASSOCIATED MICROTHROMBOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         COVID-19, the disease caused by infection with the SARS-CoV-2 virus, may be associated with microvascular thrombosis. Despite this, we do not consider COVID-19 to be a TMA, and there are no data to suggest that TMA-directed therapies are effective. Management of COVID-19 is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127419.html" rel="external">
          "COVID-19: Management of the intubated adult"
         </a>
         .)
        </p>
        <p>
         Observations that distinguish COVID-19 from primary TMAs include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autopsy studies have demonstrated microvascular thrombosis of the lungs, and, to a lesser extent, the kidneys [
         <a href="#rid63">
          63-65
         </a>
         ]. However, a hypercoagulable state associated with large vessel thrombosis is also common. (See
         <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">
          "COVID-19: Hypercoagulability"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         COVID-19 is not typically associated with microangiopathic hemolytic anemia (MAHA) or thrombocytopenia, which are the hallmarks of TMA [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In rare cases in which thrombocytopenia is seen, it may be a feature of disseminated intravascular coagulation (DIC), which is also rare in patients with COVID-19, or even immune thrombocytopenia [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">
          "COVID-19: Hypercoagulability", section on 'Coagulation abnormalities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ADAMTS13 activity levels do not appear to be severely deficient in patients with COVID-19 [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complement-mediated endothelial injury has been speculated to play a role in the microvascular thrombosis, and anti-complement agents for treatment of COVID-19 are under investigation [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1937179859">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117846.html" rel="external">
          "Society guideline links: Thrombotic microangiopathies (TTP, HUS, and related disorders)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15875938">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histopathology of TMA
         </strong>
         – The histopathology of thrombotic thrombocytopenic purpura (TTP) and other primary thrombotic microangiopathies (TMAs) is characterized by small vessel changes including swelling of endothelial cells and the subendothelial space, along with vessel wall thickening and platelet microthrombi, typically in small arterioles and capillaries. This causes thrombocytopenia and microangiopathic hemolytic anemia (MAHA). Involvement of the kidney and central nervous system is common. (See
         <a class="local">
          'Histopathology of TMA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology of primary TMAs
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          TTP
         </strong>
         – TTP is caused by severely deficient activity of the ADAMTS13 protease, typically with an activity level &lt;10 percent. ADAMTS13 cleaves newly synthesized ultralarge von Willebrand factor (VWF) multimers attached to the endothelial surface that are responsible for formation of platelet microthrombi. Most commonly, ADAMTS13 deficiency is immune, due to autoantibodies against ADAMTS13, although hereditary TTP caused by biallelic pathogenic variants in the
         <em>
          ADAMTS13
         </em>
         gene is also seen. (See
         <a class="local">
          'TTP pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CM-TMA
         </strong>
         – Dysregulation of complement is responsible for complement-mediated TMA (CM-TMA), which can affect children or adults. Autoantibodies to factors in the alternative complement pathway and heterozygosity for a pathogenic variant in a gene encoding one of these components can be seen. (See
         <a class="local">
          'Complement-mediated TMA pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ST-HUS
         </strong>
         – Enteric infection with a Shiga toxin-producing organism such as
         <em>
          Escherichia coli
         </em>
         0157:H7 is the cause of Shiga toxin-induced hemolytic uremic syndrome (ST-HUS). Although large outbreaks are widely publicized, most cases are endemic. (See
         <a class="local">
          'Shiga toxin-induced TMA (ST-HUS)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other primary TMAs
         </strong>
         – The pathogenesis of other primary TMAs, including pathogenic variants in genes encoding coagulation regulators (
         <em>
          DGKE
         </em>
         and thrombomodulin) and a vitamin B12 metabolic enzyme (
         <em>
          MMACHC
         </em>
         ) is less well understood. (See
         <a class="local">
          'Other primary TMAs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology of DITMA
         </strong>
         – Drug-induced TMA (DITMA) can result from non-immune-mediated drug toxicity (such as with certain opioids) or an immune mechanism involving activation of drug-dependent antibodies (such as with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)"
         </a>
         and
         <a class="local">
          'Drug-induced TMA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          COVID-19
         </strong>
         – Coronavirus disease 2019 (COVID-19) may be associated with microvascular thrombosis, but we do not consider this to be a primary TMA. (See
         <a class="local">
          'COVID-19-associated microthrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Distinguishing among the TMAs can be challenging. Our approach is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014; 40:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nokes T, George JN, Vesely SK, Awab A. Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. Eur J Haematol 2014; 92:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BRAIN MC, DACIE JV, HOURIHANE DO. Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis. Br J Haematol 1962; 8:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park) 2011; 25:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francis K, Kojouri K, George J. Occult systemic malignancy masquerading as thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Community Oncology 2005; 2:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zander CB, Cao W, Zheng XL. ADAMTS13 and von Willebrand factor interactions. Curr Opin Hematol 2015; 22:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shelat SG, Ai J, Zheng XL. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost 2005; 31:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayanambakkam A, Kremer Hovinga JA, Vesely SK, George JN. Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. Am J Hematol 2017; 92:E644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9 Suppl 1:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119:5888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dorland HA, Taleghani MM, Sakai K, et al. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica 2019; 104:2107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alwan F, Vendramin C, Liesner R, et al. Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood 2019; 133:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN. Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why? Transfusion 2015; 55:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen TC, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN. Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis. Thromb Haemost 2008; 99:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98:2730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mannucci PM, Parolari A, Canciani MT, et al. Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery. J Thromb Haemost 2005; 3:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Luceros A, Farías CE, Amaral MM, et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004; 92:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Studt JD, Kremer Hovinga JA, Antoine G, et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med 2014; 5:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 2013; 60:1676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppo P, Busson M, Veyradier A, et al. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. J Thromb Haemost 2010; 8:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013; 122:2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011; 9:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isonishi A, Bennett CL, Plaimauer B, et al. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion 2015; 55:2321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luken BM, Turenhout EA, Hulstein JJ, et al. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103:4514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pos W, Luken BM, Sorvillo N, et al. Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2011; 9:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varadi K, Schreiner J, Plaimauer B, et al. ADAMTS13 autoantibody detection by quantitative immunoblotting. Blood 2003; 102:1932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah N, Sarode R. Thrombotic thrombocytopenic purpura-what is new? J Clin Apher 2013; 28:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chander DP, Loch MM, Cataland SR, George JN. Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 2019; 381:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor H. Biochemistry 2013; 52:3949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofer J, Giner T, Józsi M. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. Semin Thromb Hemost 2014; 40:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner N, Sartain S, Moake J. Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes. Hematol Oncol Clin North Am 2015; 29:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One 2013; 8:e59372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner N, Nolasco L, Nolasco J, et al. Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin Thromb Hemost 2014; 40:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovacs MJ, Roddy J, Grégoire S, et al. Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to Escherichia coli O157:H7. Am J Med 1990; 88:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell BP, Goldoft M, Griffin PM, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994; 272:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchholz U, Bernard H, Werber D, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 2011; 365:1763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maki DG. Don't eat the spinach--controlling foodborne infectious disease. N Engl J Med 2006; 355:1952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bottichio L, Keaton A, Thomas D, et al. Shiga Toxin-Producing Escherichia coli Infections Associated With Romaine Lettuce-United States, 2018. Clin Infect Dis 2020; 71:e323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371:1847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemaire M, Frémeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quaggin SE. DGKE and atypical HUS. Nat Genet 2013; 45:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozaltin F, Li B, Rauhauser A, et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 2013; 24:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruneau S, Néel M, Roumenina LT, et al. Loss of DGKε induces endothelial cell activation and death independently of complement activation. Blood 2015; 125:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westland R, Bodria M, Carrea A, et al. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 2014; 25:1408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinibaldi S, Guzzo I, Piras R, et al. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant 2013; 17:E177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan X, Yoshida Y, Honda S, et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol 2013; 54:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo P, Doyon J, Sonsino E, et al. A congenital anomaly of vitamin B12 metabolism: a study of three cases. Hum Pathol 1992; 23:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geraghty MT, Perlman EJ, Martin LS, et al. Cobalamin C defect associated with hemolytic-uremic syndrome. J Pediatr 1992; 120:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornec-Le Gall E, Delmas Y, De Parscau L, et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 2014; 63:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grangé S, Bekri S, Artaud-Macari E, et al. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet 2015; 386:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN. Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised? Lancet 2015; 386:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saleem R, Reese JA, George JN. Drug-induced thrombotic microangiopathy: An updated systematic review, 2014-2018. Am J Hematol 2018; 93:E241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menter T, Haslbauer JD, Nienhold R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 2020; 77:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020; 173:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol 2020; 95:E131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murt A, Eskazan AE, Yılmaz U, et al. COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature. J Med Virol 2021; 93:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res 2020; 190:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020; 220:1.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1331 Version 55.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25119611" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Syndromes of thrombotic microangiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24799306" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24164539" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pulmonary involvement in patients with thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672704" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical practice. Thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14014893" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22010388" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Occult systemic malignancy masquerading as thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26186678" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : ADAMTS13 and von Willebrand factor interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16388417" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28815685" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21781265" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22547583" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30792199" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30770395" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Characterization and treatment of congenital thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20032506" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Survival and relapse in patients with thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25582234" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17229645" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18521503" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18521495" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11675345" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15670057" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15583740" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393734" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15367436" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24523598" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Management of thrombotic thrombocytopenic purpura: current perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23729372" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20141578" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23838348" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21294825" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26058519" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15711742" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14976043" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21535387" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12930734" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : ADAMTS13 autoantibody detection by quantitative immunoblotting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23420593" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Thrombotic thrombocytopenic purpura-what is new?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31269374" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23701234" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Functional anatomy of complement factor H.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22986360" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24799303" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26043389" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23555663" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24967890" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781103" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2405661" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to Escherichia coli O157:H7.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7933395" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22029753" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : German outbreak of Escherichia coli O104:H4 associated with sprouts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17093245" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Don't eat the spinach--controlling foodborne infectious disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31814028" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Shiga Toxin-Producing Escherichia coli Infections Associated With Romaine Lettuce-United States, 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25372103" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Syndromes of thrombotic microangiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23542698" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23619787" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : DGKE and atypical HUS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23274426" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25498910" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Loss of DGKεinduces endothelial cell activation and death independently of complement activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24511134" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Phenotypic expansion of DGKE-associated diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24118826" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23314101" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1568746" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A congenital anomaly of vitamin B12 metabolism: a study of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1593355" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cobalamin C defect associated with hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24210589" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26369474" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26369475" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29985540" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Drug-induced thrombotic microangiopathy: An updated systematic review, 2014-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32364264" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32374815" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32437596" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32129508" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Hematologic parameters in patients with COVID-19 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32497344" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32305740" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Severe COVID-19 infection associated with endothelial activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32299776" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
